dijous, 14 d’agost del 2014

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO




The U.S. Securities & Exchange Commission is launching an insider trading probe into the hostile takeover bid for Allergan by Valeant Pharmaceuticals and William Ackman's Pershing Square Capital, even as Allergan inks a $588 million deal for Taris Biomedical's Liris bladder drug and Ackman dangles the prospect of an IPO for Pershing Square.





Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles Pershing IPO

Pershing Square Capital Management, Valeant Pharmaceuticals, Allergan Inc.

News Well, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat

read more






from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1rwHUSf
Publicat per a
Etiquetes de comentaris: ,

Cap comentari:

Publica un comentari a l'entrada

Subscriure's a: Comentaris del missatge (Atom)